Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
165 hedge funds and large institutions have $1.6B invested in Esperion Therapeutics in 2017 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 49 increasing their positions, 51 reducing their positions, and 28 closing their positions.
57% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 28
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
32% more capital invested
Capital invested by funds: $1.21B → $1.6B (+$385M)
10% more funds holding
Funds holding: 150 → 165 (+15)
5% more call options, than puts
Call options by funds: $51.9M | Put options by funds: $49.2M
4% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 51
1.29% less ownership
Funds ownership: 94.04% → 92.75% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$19.1M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$17.3M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$16.2M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$14.3M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
-$42M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$16.9M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$16.6M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$10.7M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
-$7.91M |
ESPR Hedge Fund Activity: Q4 2017 in Review
165 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2017, worth a combined $1.6B — up 32% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ESPR positions and 28 closed out — a net gain of 16 holders — while 49 added to existing stakes and 51 trimmed.
The largest buyer was Millennium Management, adding an estimated $19.1M. The largest seller was Aisling Capital, exiting entirely with an estimated $42M sold.
- 165 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2017, up from 150 in Q3 2017.
- Funds reported $1.6B of Esperion Therapeutics stock for Q4 2017, up 32% quarter-over-quarter.
- 44 funds opened new Esperion Therapeutics positions in Q4 2017 and 28 closed out, a net change of +16 holders.
- The largest Esperion Therapeutics buyer in Q4 2017 was Millennium Management, an estimated $19.1M added.
- The largest Esperion Therapeutics seller in Q4 2017 was Aisling Capital, an estimated $42M sold.
Based on aggregated 13F filings for Q4 2017.